Isoma, which launched last year, will use the funds to develop and clinically validate a molecular test for stratifying glioblastoma patients.
Investigators have established hundreds of patient-derived xenografts, cell lines, and tumor samples, which appear to represent a wide range of melanoma molecular subtypes.
The company has achieved even higher specificity than earlier data demonstrated, and is now building up its sales and marketing infrastructure for the planned launch of its lung cancer test.
OncoCyte is proceeding full-steam ahead on commercializing the gene expression-based test, pursuing CLIA certification and a Q2 2017 launch.
The partnership will place the Graham Cancer Center's Gene Editing Institute under the purview of the Wistar Institute's Molecular Screening Facility.
The partners will identify novel drug targets in cancer, aging, and immune disorders, for which PhoreMost will develop small-molecule therapeutics.
Researchers believe the expression of Gabra3 promotes breast cancer metastasis, but that an RNA-edited form of Gabra3 suppresses it.
Last year, Wistar researchers presented data showing that the test could distinguish patients with malignant lung nodules from those with benign or no nodules.
The partners will further develop a non-invasive, blood-based test for the early detection of lung cancer.
The consortium will conduct research into how metastatic breast cancer cells break away and spread to other organs.
This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.
The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.
Researchers find that people's genetics influence their success at university, but that it is not the only factor.
In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.